Sovaprevir

Sovaprevir

Error creating thumbnail:

Chemical structure of Sovaprevir

Sovaprevir is an investigational antiviral drug that was developed for the treatment of hepatitis C virus (HCV) infection. It is a protease inhibitor that targets the NS3/4A serine protease, an enzyme essential for the replication of the hepatitis C virus.

Mechanism of Action

Sovaprevir works by inhibiting the NS3/4A serine protease, which is crucial for the viral replication process. By blocking this enzyme, sovaprevir prevents the virus from processing its polyprotein into functional viral proteins, thereby halting the replication of the virus within the host cells.

Clinical Development

Sovaprevir was developed as part of a combination therapy for the treatment of chronic hepatitis C. It was studied in various clinical trials to assess its efficacy and safety in combination with other antiviral agents, such as ribavirin and interferon.

Pharmacokinetics

The pharmacokinetic profile of sovaprevir includes its absorption, distribution, metabolism, and excretion. Sovaprevir is administered orally and undergoes hepatic metabolism. The drug is primarily excreted via the feces, with a minor portion eliminated through the urine.

Side Effects

Common side effects associated with sovaprevir include nausea, fatigue, and headache. As with other protease inhibitors, there is a potential for drug-drug interactions, particularly with medications that are metabolized by the cytochrome P450 enzyme system.

Current Status

As of the latest updates, sovaprevir is not approved for clinical use and remains an investigational drug. Research and development efforts continue to explore its potential in combination therapies for hepatitis C.

Related Pages

• Hepatitis C
• Antiviral drug
• Protease inhibitor
• NS3/4A serine protease